Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 9/2015

Open Access 01-12-2015 | Original Paper

Health state utilities associated with attributes of treatments for hepatitis C

Authors: Louis S. Matza, Sandhya J. Sapra, John F. Dillon, Anupama Kalsekar, Evan W. Davies, Mary K. Devine, Jessica B. Jordan, Amanda S. Landrian, David H. Feeny

Published in: The European Journal of Health Economics | Issue 9/2015

Login to get access

Abstract

Background

Cost-utility analyses are frequently conducted to compare treatments for hepatitis C, which are often associated with complex regimens and serious adverse events. Thus, the purpose of this study was to estimate the utility associated with treatment administration and adverse events of hepatitis C treatments.

Design

Health states were drafted based on literature review and clinician interviews. General population participants in the UK valued the health states in time trade-off (TTO) interviews with 10- and 1-year time horizons. The 14 health states described hepatitis C with variations in treatment regimen and adverse events.

Results

A total of 182 participants completed interviews (50 % female; mean age = 39.3 years). Utilities for health states describing treatment regimens without injections ranged from 0.80 (1 tablet) to 0.79 (7 tablets). Utilities for health states describing oral plus injectable regimens were 0.77 (7 tablets), 0.75 (12 tablets), and 0.71 (18 tablets). Addition of a weekly injection had a disutility of −0.02. A requirement to take medication with fatty food had a disutility of −0.04. Adverse events were associated with substantial disutilities: mild anemia, −0.12; severe anemia, −0.32; flu-like symptoms, −0.21; mild rash, −0.13; severe rash, −0.48; depression, −0.47. One-year TTO scores were similar to these 10-year values.

Conclusions

Adverse events and greater treatment regimen complexity were associated with lower utility scores, suggesting a perceived decrease in quality of life beyond the impact of hepatitis C. The resulting utilities may be used in models estimating and comparing the value of treatments for hepatitis C.
Appendix
Available only for authorised users
Literature
1.
Cornberg, M., Razavi, H.A., Alberti, A., Bernasconi, E., Buti, M., Cooper, C., Dalgard, O., Dillion, J.F., Flisiak, R., Forns, X., et al.: A systematic review of hepatitis C virus epidemiology in Europe Canada and Israel. Liver Int. 31(Suppl 2), 30–60 (2011)CrossRefPubMed
2.
3.
Ward, J.W.: The epidemiology of chronic hepatitis C and one-time hepatitis C virus testing of persons born during 1945 to 1965 in the United States. Clin. Liver Dis. 17, 1–11 (2013)CrossRefPubMed
4.
5.
Strader, D.B., Seeff, L.B.: The natural history of chronic hepatitis C infection. Eur. J. Gastroenterol. Hepatol. 8, 324–328 (1996)CrossRefPubMed
6.
Te, H.S., Jensen, D.M.: Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 14, 1–21, vii (2010)CrossRefPubMed
7.
8.
9.
Freeman, A.J., Dore, G.J., Law, M.G., Thorpe, M., Von Overbeck, J., Lloyd, A.R., Marinos, G., Kaldor, J.M.: Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 34, 809–816 (2001)CrossRefPubMed
10.
Maasoumy, B., Wedemeyer, H.: Natural history of acute and chronic hepatitis C. Best Pract. Res. Clin. Gastroenterol. 26, 401–412 (2012)CrossRefPubMed
11.
McDonald, S.A., Hutchinson, S.J., Bird, S.M., Mills, P.R., Hayes, P., Dillon, J.F., Goldberg, D.J.: Excess morbidity in the hepatitis C-diagnosed population in Scotland, 1991–2006. Epidemiol. Infect. 139, 344–353 (2011)CrossRefPubMed
12.
Omland, L.H., Farkas, D.K., Jepsen, P., Obel, N., Pedersen, L.: Hepatitis C virus infection and risk of cancer: a population-based cohort study. Clin. Epidemiol. 2, 179–186 (2010)PubMedCentralCrossRefPubMed
13.
Food and Drug Administration Center for Drug Evaluation and Research (CDER): Guidance for industry chronic hepatitis C virus infection: developing direct-acting antiviral drugs for treatment. Revision 1 edition. Silver Spring, MD, October (2013)
14.
Ghany, M.G., Strader, D.B., Thomas, D.L., Seeff, L.B., American Association for the Study of Liver D: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49, 1335–1374 (2009)CrossRefPubMed
15.
Munteanu, D.I., Rockstroh, J.K.: New agents for the treatment of hepatitis C in patients co-infected with HIV. Ther. Adv. Infect. Dis. 1, 71–80 (2013)PubMedCentralPubMed
16.
Sitole, M., Silva, M., Spooner, L., Comee, M.K., Malloy, M.: Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. Clin. Ther. 35, 190–197 (2013)CrossRefPubMed
17.
Bota, S., Sporea, I., Sirli, R., Popescu, A., Neghina, A.M., Danila, M., Strain, M.: Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: a systematic review. World J. Hepatol. 5, 120–126 (2013)PubMedCentralCrossRefPubMed
18.
Manos, M.M., Ho, C.K., Murphy, R.C., Shvachko, V.A.: Physical, social, and psychological consequences of treatment for hepatitis C: a community-based evaluation of patient-reported outcomes. Patient 6, 23–34 (2013)PubMedCentralCrossRefPubMed
19.
Modabbernia, A., Poustchi, H., Malekzadeh, R.: Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review. Hepat. Mon. 13, e8340 (2013)PubMedCentralCrossRefPubMed
20.
Rosa, I.: Management of side-effects. Clin. Res. Hepatol. Gastroenterol. 35(Suppl 2), S69–S74 (2011)CrossRefPubMed
21.
Alam, I., Stainbrook, T., Cecil, B., Kistler, K.D.: Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry. Aliment. Pharmacol. Ther. 32, 535–542 (2010)CrossRefPubMed
22.
Brett Hauber, A., Mohamed, A.F., Beam, C., Medjedovic, J., Mauskopf, J.: Patient preferences and assessment of likely adherence to hepatitis C virus treatment. J. Viral Hepat. 18, 619–627 (2011)CrossRefPubMed
23.
Ravi, S., Nasiri Toosi, M., Karimzadeh, I., Ahadi-Barzoki, M., Khalili, H.: Adherence to chronic hepatitis C treatment regimen: first report from a referral center in Iran. Hepat. Mon. 13, e11038 (2013)PubMedCentralCrossRefPubMed
24.
Sun, X., Patnode, C., Williams, C., Senger, C., Kapka, T., Whitlock, E.: Interventions to improve patient adherence to hepatitis C treatment: comparative effectiveness. Comparative effectiveness review no. 91. (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-2007-10057-I.): AHRQ Publication No. 13-EHC009-EF. Rockville, MD: Agency for Healthcare Research and Quality, December (2012)
25.
Afdhal, N.H., Zeuzem, S., Schooley, R.T., Thomas, D.L., Ward, J.W., Litwin, A.H., Razavi, H., Castera, L., Poynard, T., Muir, A., et al.: The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J. Viral Hepat. 20, 745–760 (2013)PubMedCentralCrossRefPubMed
26.
Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S.C., Schultz, M., Davis, M.N., Kayali, Z., Reddy, K.R., et al.: Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368, 1878–1887 (2013)CrossRefPubMed
27.
Lok, A.S., Gardiner, D.F., Lawitz, E., Martorell, C., Everson, G.T., Ghalib, R., Reindollar, R., Rustgi, V., McPhee, F., Wind-Rotolo, M., et al.: Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366, 216–224 (2012)CrossRefPubMed
28.
Pollack, A,: Hepatitis C, a silent killer, meets its match. New York Times, New York edn. New York, NY: The New York Times Company (2013)
29.
Casey, L.C., Lee, W.M.: Hepatitis C virus therapy update 2013. Curr Opin Gastroenterol 29, 243–249 (2013)PubMed
30.
Muir, A.J.: The rapid evolution of treatment strategies for hepatitis C. Am. J. Gastroenterol. 109, 628–635 (2014)CrossRefPubMed
31.
Brogan, A.J., Talbird, S.E., Thompson, J.R., Miller, J.D., Rubin, J., Deniz, B.: Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C. PLoS ONE 9, e90295 (2014)PubMedCentralCrossRefPubMed
32.
Martin, N.K., Hickman, M., Miners, A., Hutchinson, S.J., Taylor, A., Vickerman, P.: Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open, 3, e003153 (2013)
33.
Martin, N.K., Vickerman, P., Miners, A., Foster, G.R., Hutchinson, S.J., Goldberg, D.J., Hickman, M.: Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 55, 49–57 (2012)CrossRefPubMed
34.
McEwan, P., Kim, R., Yuan, Y.: Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. Appl. Health Econ. Health Policy 11, 53–63 (2013)CrossRefPubMed
35.
Siebert, U., Sroczynski, G., Aidelsburger, P., Rossol, S., Wasem, J., Manns, M.P., McHutchison, J.G., Wong, J.B.: Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines. Pharmacoeconomics 27, 341–354 (2009)CrossRefPubMed
36.
Siebert, U., Sroczynski, G., Rossol, S., Wasem, J., Ravens-Sieberer, U., Kurth, B.M., Manns, M.P., McHutchison, J.G., Wong, J.B.: German hepatitis CMG, international hepatitis interventional therapy G: cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 52, 425–432 (2003)PubMedCentralCrossRefPubMed
37.
Townsend, R., McEwan, P., Kim, R., Yuan, Y.: Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health 14, 1068–1077 (2011)CrossRefPubMed
38.
Feeny, D.: Preference-based measures: utility and quality-adjusted life years. In: Fayers, P., Hays, R. (eds.) Assessing quality of life in clinical trials, 2nd edn, pp. 405–431. Oxford University Press, New York (2005)
39.
Rowen, D., Brazier, J.: Health utility measurement. In: Glied, S., Smith, P. (eds.) The Oxford Handbook of Health Economics, pp. 788–813. Oxford University Press, New York (2011)
40.
McLernon, D.J., Dillon, J., Donnan, P.T.: Health-state utilities in liver disease: a systematic review. Med. Decis. Mak. 28, 582–592 (2008)CrossRef
41.
Sherman, K.E., Sherman, S.N., Chenier, T., Tsevat, J.: Health values of patients with chronic hepatitis C infection. Arch. Intern. Med. 164, 2377–2382 (2004)CrossRefPubMed
42.
Wright, M., Grieve, R., Roberts, J., Main, J., Thomas, H.C., U. k. Mild Hepatitis C Trial Investigators: Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol. Assess. 10, 1–113 (2006)CrossRef
43.
Younossi, Z.M., Boparai, N., McCormick, M., Price, L.L., Guyatt, G.: Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am. J. Gastroenterol. 96, 579–583 (2001)CrossRefPubMed
44.
Hsu, P.C., Federico, C.A., Krajden, M., Yoshida, E.M., Bremner, K.E., Anderson, F.H., Weiss, A.A., Krahn, M.D.: Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J. Gastroenterol. Hepatol. 27, 149–157 (2012)CrossRefPubMed
45.
Kerr, C., Lloyd, A., Ali, S., Gore, C., Tyas, D.A.: Impact of treatment attributes of peginterferon for hepatitis C on quality of life and treatment preference. Health Outcomes Res. Med. 3, e153–e167 (2012)CrossRef
46.
Cooper, C., Lester, R., Thorlund, K., Druyts, E., El Khoury, A.C., Yaya, S., Mills, E.J.: Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. QJM 106, 153–163 (2013)PubMedCentralCrossRefPubMed
47.
Jin, Y.J., Lee, J.W., Lee, J.I., Park, S.H., Park, C.K., Kim, Y.S., Jeong, S.H., Kim, Y.S., Kim, J.H., Hwang, S.G., et al.: Multicenter comparison of PEG-IFN alpha2a or alpha2b plus ribavirin for treatment-naive HCV patient in Korean population. BMC Gastroenterol. 13, 74 (2013)PubMedCentralCrossRefPubMed
48.
Rabin, R., Oemar, M., Oppe, M.: EQ-5D-3L User guide: basic information on how to use the EQ-5D-3L instrument. (EuroQol Group Executive Office ed., Version 4.0 edition. Rotterdam, The Netherlands: EuroQol Group, pp. 1–21 (2011)
49.
Horsman, J., Furlong, W., Feeny, D., Torrance, G.: The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual. Life Outcomes 1, 54 (2003)PubMedCentralCrossRefPubMed
50.
Chancellor, J., Aballea, S., Lawrence, A., Sheldon, R., Cure, S., Plun-Favreau, J., Marchant, N.: Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens. Pharmacoeconomics 26, 217–234 (2008)CrossRefPubMed
51.
Boye, K.S., Matza, L.S., Walter, K.N., Van Brunt, K., Palsgrove, A.C., Tynan, A.: Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur. J. Health Econ. 12, 219–230 (2011)CrossRefPubMed
52.
Osborne, R.H., Dalton, A., Hertel, J., Schrover, R., Smith, D.K.: Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study. Health Qual. Life Outcomes 10, 35 (2012)PubMedCentralCrossRefPubMed
53.
Teuffel, O., Cheng, S., Ethier, M.C., Diorio, C., Martino, J., Mayo, C., Wing, R., Sung, L., Alibhai, S.M.: Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients Support. Care Cancer 20, 2755–2764 (2012)CrossRef
54.
Feeny, D., Townsend, M., Furlong, W., Tomkins, D.J., Robinson, G.E., Torrance, G.W., Mohide, P.T., Wang, Q.: Health-related quality-of-life assessment of prenatal diagnosis: chorionic villi sampling and amniocentesis. Genet Test 6, 39–46 (2002)CrossRefPubMed
55.
Jewell, E.L., Smrtka, M., Broadwater, G., Valea, F., Davis, D.M., Nolte, K.C., Valea, R., Myers, E.R., Samsa, G., Havrilesky, L.J.: Utility scores and treatment preferences for clinical early-stage cervical cancer. Value Health 14, 582–586 (2011)CrossRefPubMed
56.
Wu, J.M., Fulton, R.G., Amundsen, C.L., Knight, S.K., Kuppermann, M.: Patient preferences for different severities of and treatments for overactive bladder. Female Pelvic Med. Reconstr. Surg. 17, 184–189 (2011)CrossRefPubMed
57.
Chou, R., Hartung, D., Rahman, B., Wasson, N., Cottrell, E., Fu, R.: Treatment for Hepatitis C virus infection in adults. Comparative effectiveness review No. 76. (Prepared by Oregon Evidence-based Practice Center under Contract No. 290-2007-10057-I.): AHRQ Publication No. 12(13)-EHC113-EF. Rockville, MD: Agency for Healthcare Research and Quality, November (2012)
58.
Rajani, A.K., Ravindra, B.K., Dkhar, S.A.: Telaprevir: changing the standard of care of chronic hepatitis C. J. Postgrad. Med. 59, 42–47 (2013)CrossRefPubMed
59.
Teixeira, R., Nascimento Yde, A., Crespo, D.: Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions. Braz. J. Infect. Dis. 17, 194–204 (2013)CrossRefPubMed
60.
Udina, M., Castellvi, P., Moreno-Espana, J., Navines, R., Valdes, M., Forns, X., Langohr, K., Sola, R., Vieta, E., Martin-Santos, R.: Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J. Clin. Psychiatry 73, 1128–1138 (2012)CrossRefPubMed
61.
Dolan, P.: Modelling valuations for health states: the effect of duration. Health Policy 38, 189–203 (1996)CrossRefPubMed
62.
63.
Gane, E.J., Stedman, C.A., Hyland, R.H., Ding, X., Svarovskaia, E., Symonds, W.T., Hindes, R.G., Berrey, M.M.: Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368, 34–44 (2013)CrossRefPubMed
64.
Souvignet, C., Lejeune, O., Trepo, C.: Interferon-based treatment of chronic hepatitis C. Biochimie 89, 894–898 (2007)CrossRefPubMed
65.
Janssen-Cilag Pharmaceuticals: Summary of product characteristics: Incivo 375 mg film-coated tablets telaprevir. In Labelling, Package Leaflet. Latina, Italy: European Public Assessment Reports (EPAR)
66.
Kiang, T.K., Wilby, K.J., Ensom, M.H.: Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions. Clin. Pharmacokinet. 52, 487–510 (2013)CrossRefPubMed
67.
68.
Gordon, S.C., Yoshida, E.M., Lawitz, E.J., Bacon, B.R., Sulkowski, M.S., Davis, M., Poordad, F., Bronowicki, J.P., Esteban, R., Sniukiene, V., et al.: Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin. Aliment. Pharmacol. Ther. 38, 16–27 (2013)CrossRefPubMed
69.
Merck Sharp & Dohme: Summary of product characteristics: victrelis 200 mg hard capsules boceprevir. In Labelling, Package Leaflet. Hertfordshire, UK: European Public Assessment Reports (EPAR). Last updated on eMC 11 September 2014
70.
Chou, R., Hartung, D., Rahman, B., Wasson, N., Cottrell, E.B., Fu, R.: Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann. Intern. Med. 158, 114–123 (2013)CrossRefPubMed
71.
Koretz, R.L., Pleguezuelo, M., Arvaniti, V., Barrera Baena, P., Ciria, R., Gurusamy, K.S., Davidson, B.R., Burroughs, A.K.: Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Datab. Syst. Rev. 1, CD003617 (2013)
72.
SP (Brinny) Company: Summary of product characteristics: IntronA 3 million IU/0.5 ml solution for injection or infusion interferon alfa-2b. In Labelling, Package Leaflet. County Cork, Ireland: European Public Assessment Reports (EPAR)
73.
Penn Pharmaceutical Services: Summary of product characteristics: Ribavirin Mylan 200 mg hard capsules In Labelling, Package Leaflet. Gwent County, UK: European Public Assessment Reports (EPAR)
74.
Brazier, J.: Valuing health states for use in cost-effectiveness analysis. Pharmacoeconomics 26, 769–779 (2008)CrossRefPubMed
75.
CADTH (Canadian Agency for Drugs and Technologies in Health): Guidelines for the economic evaluation of health technologies: Canada [3rd] edition. Ottawa: Canadian Agency for Drugs and Technologies in Health (2006)
76.
NICE (National Institute for Health and Clinical Excellence): Process and methods guides: guide to the methods of technology appraisal 2013. London, UK: National Institute for Health and Clinical Excellence (2013)
77.
PBAC (Pharmaceutical Benefits Advisory Committee): Guidelines for preparing submissions to PBAC, Version 4.3.2. PBAC (2008)
78.
Dolan, P., Gudex, C., Kind, P., Williams, A.: The time trade-off method: results from a general population study. Health Econ. 5, 141–154 (1996)CrossRefPubMed
79.
Arnesen, T., Trommald, M.: Are QALYs based on time trade-off comparable?—a systematic review of TTO methodologies. Health Econ. 14, 39–53 (2005)CrossRefPubMed
80.
Chen, C.L., Kuppermann, M., Caughey, A.B., Zane, L.T.: A community-based study of acne-related health preferences in adolescents. Arch. Dermatol. 144, 988–994 (2008)PubMed
81.
Guest, J.F., Naik, N., Sladkevicius, E., Coombs, J., Gray, E.J.: Utility values for chronic myelogenous leukemia chronic phase health states from the general public in the United Kingdom. Leuk. Lymphoma 53, 928–933 (2012)CrossRefPubMed
82.
Matza, L.S., Chung, K., Van Brunt, K., Brazier, J.E., Braun, A., Currie, B., Palsgrove, A., Davies, E., Body, J.J.: Health state utilities for skeletal-related events secondary to bone metastases. Eur. J. Health Econ. 15, 7–18 (2014)PubMedCentralCrossRefPubMed
83.
Saw, S.M., Gazzard, G., Gomezperalta, C., Au Eong, K.G., Seah, S.: Utility assessment among cataract surgery patients. J. Cataract Refract. Surg. 31, 785–791 (2005)CrossRefPubMed
84.
Schmitt, J., Meurer, M., Klon, M., Frick, K.D.: Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. Br. J. Dermatol. 158, 351–359 (2008)CrossRefPubMed
85.
Stevenson, L.W., Hellkamp, A.S., Leier, C.V., Sopko, G., Koelling, T., Warnica, J.W., Abraham, W.T., Kasper, E.K., Rogers, J.G., Califf, R.M., et al.: Changing preferences for survival after hospitalization with advanced heart failure. J. Am. Coll. Cardiol. 52, 1702–1708 (2008)PubMedCentralCrossRefPubMed
86.
Brazier, J.R., Ratcliffe, J., Salomon, J.A., Tsuchiya, A.: Measuring and valuing health benefits for economic evaluation. Oxford University Press, New York (2007)
87.
Brennan, V.K., Dixon, S.: Incorporating process utility into quality adjusted life years: a systematic review of empirical studies. Pharmacoeconomics 31, 677–691 (2013)CrossRefPubMed
88.
Matza, L.S., Cong, Z., Chung, K., Stopeck, A., Tonkin, K., Brown, J., Braun, A., Van Brunt, K., McDaniel, K.: Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases. Patient Prefer Adher. 7, 855–865 (2013)CrossRef
89.
Bennett, K.J., Torrance, G.W., Boyle, M.H., Guscott, R., Moran, L.A.: Development and testing of a utility measure for major, unipolar depression (McSad). Qual. Life Res. 9, 109–120 (2000)CrossRefPubMed
90.
Revicki, D.A., Wood, M.: Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J. Affect. Disord. 48, 25–36 (1998)CrossRefPubMed
91.
Sapin, C., Fantino, B., Nowicki, M.L., Kind, P.: Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual. Life Outcomes 2, 20 (2004)PubMedCentralCrossRefPubMed
92.
Sobocki, P., Ekman, M., Agren, H., Krakau, I., Runeson, B., Martensson, B., Jonsson, B.: Health-related quality of life measured with EQ-5D in patients treated for depression in primary care. Value Health 10, 153–160 (2007)CrossRefPubMed
93.
Drummond, M.: Introducing economic and quality of life measurements into clinical studies. Ann. Med. 33, 344–349 (2001)CrossRefPubMed
94.
Kaplan, R.M.: The minimally clinically important difference in generic utility-based measures. COPD 2, 91–97 (2005)CrossRefPubMed
95.
Luo, N., Johnson, J., Coons, S.J.: Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments. Med. Care 48, 365–371 (2010)CrossRefPubMed
96.
Marra, C.A., Woolcott, J.C., Kopec, J.A., Shojania, K., Offer, R., Brazier, J.E., Esdaile, J.M., Anis, A.H.: A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc. Sci. Med. 60, 1571–1582 (2005)CrossRefPubMed
97.
Pickard, A.S., Neary, M.P., Cella, D.: Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 5, 70 (2007)PubMedCentralCrossRefPubMed
98.
Furlong, W., Feeny, D.H., Torrance, G.W., et al.: Guide to design and development of health-state utility instrumentation. Hamilton, ON: McMaster University, Report No. 90-99 (1990)
99.
Lin, M.R., Yu, W.Y., Wang, S.C.: Examination of assumptions in using time tradeoff and standard gamble utilities in individuals with spinal cord injury. Arch. Phys. Med. Rehabil. 93, 245–252 (2012)CrossRefPubMed
100.
Matza, L.S., Boye, K.S., Feeny, D.H., Bowman, L., Johnston, J.A., McDaniel, K., Jordan, J., Devine, K., Davies, E.: The time horizon matters: exploratory results varying the time horizon in time trade-off and standard gamble utility elicitation. In ISPOR 15th Annual European Congress; November 3–7, 2012, Berlin, Germany (2012)
101.
Stiggelbout, A.M., Kiebert, G.M., Kievit, J., Leer, J.W., Habbema, J.D., De Haes, J.C.: The “utility” of the time trade-off method in cancer patients: feasibility and proportional trade-off. J. Clin. Epidemiol. 48, 1207–1214 (1995)CrossRefPubMed
102.
van Nooten, F.E., Koolman, X., Brouwer, W.B.: The influence of subjective life expectancy on health state valuations using a 10 year TTO. Health Econ. 18, 549–558 (2009)CrossRefPubMed
103.
van Nooten, F.E., Koolman, X., Busschbach, J.J., Brouwer, W.B.: Thirty down, only ten to go?! Awareness and influence of a 10-year time frame in TTO. Qual. Life Res. 23, 377–384 (2013)
104.
Gerard, K., Dobson, M., Hall, J.: Framing and labelling effects in health descriptions: quality adjusted life years for treatment of breast cancer. J. Clin. Epidemiol. 46, 77–84 (1993)CrossRefPubMed
105.
Rowen, D., Brazier, J., Tsuchiya, A., Young, T., Ibbotson, R.: It’s all in the name, or is it? The impact of labeling on health state values. Med. Decis. Mak. 32, 31–40 (2012)CrossRef
106.
Sackett, D.L., Torrance, G.W.: The utility of different health states as perceived by the general public. J. Chronic. Dis. 31, 697–704 (1978)CrossRefPubMed
Metadata
Title
Health state utilities associated with attributes of treatments for hepatitis C
Authors
Louis S. Matza
Sandhya J. Sapra
John F. Dillon
Anupama Kalsekar
Evan W. Davies
Mary K. Devine
Jessica B. Jordan
Amanda S. Landrian
David H. Feeny
Publication date
01-12-2015
Publisher
Springer Berlin Heidelberg
Published in
The European Journal of Health Economics / Issue 9/2015
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-014-0649-6

Other articles of this Issue 9/2015

The European Journal of Health Economics 9/2015 Go to the issue

Original Paper

Parallel imports and a mandatory substitution reform: a kick or a muff for price competition in pharmaceuticals?

Original Paper

An examination of the relationships between service use and alternative measures of obesity among community-dwelling adults in Ireland

Original Paper

Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD)

Original Paper

Some economics on personalized and predictive medicine

Original Paper

Endogenous risk-taking and physical appearance of sex workers

Original Paper

Health burden and costs of obesity and overweight in Germany: an update